Wall Street brokerages predict that La Jolla Pharmaceutical (NASDAQ:LJPC) will announce ($1.91) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for La Jolla Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($1.97) and the highest estimate coming in at ($1.80). La Jolla Pharmaceutical posted earnings per share of ($1.21) during the same quarter last year, which suggests a negative year-over-year growth rate of 57.9%. The company is scheduled to report its next quarterly earnings report on Thursday, July 26th.
On average, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($7.32) per share for the current financial year, with EPS estimates ranging from ($8.05) to ($5.34). For the next year, analysts expect that the business will report earnings of ($4.14) per share, with EPS estimates ranging from ($5.79) to ($1.51). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover La Jolla Pharmaceutical.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($2.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.74). The firm had revenue of $0.81 million for the quarter.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd acquired a new position in La Jolla Pharmaceutical in the first quarter valued at approximately $276,000. LPL Financial LLC acquired a new position in La Jolla Pharmaceutical in the fourth quarter valued at approximately $434,000. MetLife Investment Advisors LLC acquired a new position in La Jolla Pharmaceutical in the fourth quarter valued at approximately $276,000. BlackRock Inc. lifted its holdings in La Jolla Pharmaceutical by 1.4% in the fourth quarter. BlackRock Inc. now owns 1,177,575 shares of the biopharmaceutical company’s stock valued at $37,893,000 after buying an additional 15,934 shares during the period. Finally, Asymmetry Capital Management L.P. acquired a new position in La Jolla Pharmaceutical in the first quarter valued at approximately $1,664,000.
Shares of LJPC traded down $1.50 during mid-day trading on Wednesday, hitting $32.51. 481,041 shares of the company traded hands, compared to its average volume of 445,992. La Jolla Pharmaceutical has a one year low of $22.68 and a one year high of $41.36. The stock has a market capitalization of $886.64 million, a P/E ratio of -6.01 and a beta of 1.35.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Recommended Story: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.